FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000818610> ?p ?o ?g. }

• W2000818610 abstract "Background: Deletion of 17p (17p–) is the principal predictor of poor outcome in chronic lymphocytic leukemia (CLL) patients after conventional chemotherapy. Several reports have shown better outcomes with non-myeloablative allogeneic stem cell transplantation (NST). However, questions have been raised as to the relevance of NST, in particular, the extent that various selection biases lead to selection of only the ‘best’ patients for this procedure. Purpose: Our primary goal was to update our NST experience with 17p–, and report how often patients underwent transplantation and, within the limits of a retrospective analysis, the reasons for not undergoing transplantation. Methods: We reviewed NST outcomes for 17p– CLL patients transplanted between 2005 (when FISH became routinely performed at our institution) and 2010. Given the poor outcome after conventional fludarabine, cyclophosphamide, and rituximab (FCR) therapy, a diligent effort was started by the leukemia service in 2007 to refer patients to transplant sooner rather than later. Therefore, in a subanalysis, we reviewed the number of 17p– CLL patients who were referred to the transplant consult service from 2007 and assessed the reasons for no transplant. Prognostic factors were evaluated using Cox’s regression model. Multivariate analysis was not possible given sample size limitations. Results: Outcome of NST in 17p– CLL patients: Twenty-six patients were transplanted at our institution between 2005 and 2010. The median age was 56 years (range 37–73 years). At NST, 15 patients (58%) had 2-microglobulin ( 2m) 3; 21/24 patients (87%) had Binet stage B/C disease; 4 patients (15%) had Richter’s syndrome; 16/25 patients (64%) were FDG-avid; the median number of prior chemotherapies was 4 (range 2–14); and 14 patients (54%) had refractory disease. Thirteen patients (50%) had complex cytogenetic abnormalities (in addition to 17p–). IGVH was unmutated in 11/12 patients (92%) tested and 14/15 (93%) were ZAP-70 positive. Prior to their transplantation, 24 patients (92%) were exposed to FCR, 11 (42%) to FCR plus alemtuzumab or oxaliplatin, 7 (27%) to hyper-CVAD, and 17 (65%) to alemtuzumab. With a median follow-up of 18 months (range 3–60 months), 2-year overall survival (OS) and progression-free survival (PFS) rates were 62% and 38%, respectively. On univariate analysis, determinants of outcomes included disease status, 2m at NST, and year of transplant. All but 1 patient with chemosensitive disease had 2m 4, compared with 50% of patients with chemoresistant disease. Chemosensitivity was associated with significantly higher PFS (73% vs 12%, p 0.02; Figure) and a trend toward higher OS (91% vs 45%, p 0.09). PFS was also significantly higher for transplants performed after 2007 (44% vs 20%, p 0.03). 2m 4 was associated with lower 18 month OS (36% vs 71%, p 0.05) in chemoresistant patients, but did not significantly impact PFS (38% vs 14%, p 0.5). Two years’ follow-up was not reached for 2m 4 in this group. Transplant consults and transplantation rate: Between September 2007 and March 2010, 59 patients with 17p– CLL received a transplant service consult. Twenty of these patients (34%) had received a transplant at the time of this analysis, whereas 39 (66%) had not. Reasons for not receiving transplants included: (1) death with salvage pre-transplant chemotherapy (n 14, 36%); (2) patient and/or physician became uninterested after achieving a good response to salvage chemotherapy (n 14, 36%); (3) lost to follow-up after the initial consultation (n 3, 8%); (4) age 75 years (n 2, 5%); (5) insurance denial (n 3, 8%); (6) no donor (n 1, 2%); and (7) other (n 2, 5%). Conclusions: NST is plausibly more effective in 17p– CLL patients when recipients have chemosensitive disease. If, as suggested by our analysis, at most 34% of patients receive this procedure, methods to extend the applicability of transplant are needed. Perhaps the most effective method would be to use NST as consolidation after an initial response to conventional chemotherapy. Such a strategy would allow more patients to have chemosensitive disease at NST, and would decrease the death rate in heavily pre-treated patients during pre-transplant cytoreductive therapy." @default.
• W2000818610 created "2016-06-24" @default.
• W2000818610 creator A5000721320 @default.
• W2000818610 creator A5016431955 @default.
• W2000818610 creator A5027575595 @default.
• W2000818610 creator A5028845635 @default.
• W2000818610 creator A5033737136 @default.
• W2000818610 creator A5040173294 @default.
• W2000818610 creator A5047522685 @default.
• W2000818610 creator A5051888251 @default.
• W2000818610 creator A5059138314 @default.
• W2000818610 date "2011-10-01" @default.
• W2000818610 modified "2023-09-27" @default.
• W2000818610 title "5.39 Feasibility Analysis of Non-myeloablative Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia and 17p Deletion" @default.
• W2000818610 doi "https://doi.org/10.1016/j.clml.2011.09.193" @default.
• W2000818610 hasPublicationYear "2011" @default.
• W2000818610 type Work @default.
• W2000818610 sameAs 2000818610 @default.
• W2000818610 citedByCount "0" @default.
• W2000818610 crossrefType "journal-article" @default.
• W2000818610 hasAuthorship W2000818610A5000721320 @default.
• W2000818610 hasAuthorship W2000818610A5016431955 @default.
• W2000818610 hasAuthorship W2000818610A5027575595 @default.
• W2000818610 hasAuthorship W2000818610A5028845635 @default.
• W2000818610 hasAuthorship W2000818610A5033737136 @default.
• W2000818610 hasAuthorship W2000818610A5040173294 @default.
• W2000818610 hasAuthorship W2000818610A5047522685 @default.
• W2000818610 hasAuthorship W2000818610A5051888251 @default.
• W2000818610 hasAuthorship W2000818610A5059138314 @default.
• W2000818610 hasConcept C126322002 @default.
• W2000818610 hasConcept C141071460 @default.
• W2000818610 hasConcept C143998085 @default.
• W2000818610 hasConcept C2776694085 @default.
• W2000818610 hasConcept C2776755627 @default.
• W2000818610 hasConcept C2777938653 @default.
• W2000818610 hasConcept C2778461978 @default.
• W2000818610 hasConcept C2779015954 @default.
• W2000818610 hasConcept C2779263901 @default.
• W2000818610 hasConcept C2779338263 @default.
• W2000818610 hasConcept C2780653079 @default.
• W2000818610 hasConcept C2911091166 @default.
• W2000818610 hasConcept C50382708 @default.
• W2000818610 hasConcept C71924100 @default.
• W2000818610 hasConceptScore W2000818610C126322002 @default.
• W2000818610 hasConceptScore W2000818610C141071460 @default.
• W2000818610 hasConceptScore W2000818610C143998085 @default.
• W2000818610 hasConceptScore W2000818610C2776694085 @default.
• W2000818610 hasConceptScore W2000818610C2776755627 @default.
• W2000818610 hasConceptScore W2000818610C2777938653 @default.
• W2000818610 hasConceptScore W2000818610C2778461978 @default.
• W2000818610 hasConceptScore W2000818610C2779015954 @default.
• W2000818610 hasConceptScore W2000818610C2779263901 @default.
• W2000818610 hasConceptScore W2000818610C2779338263 @default.
• W2000818610 hasConceptScore W2000818610C2780653079 @default.
• W2000818610 hasConceptScore W2000818610C2911091166 @default.
• W2000818610 hasConceptScore W2000818610C50382708 @default.
• W2000818610 hasConceptScore W2000818610C71924100 @default.
• W2000818610 hasLocation W20008186101 @default.
• W2000818610 hasOpenAccess W2000818610 @default.
• W2000818610 hasPrimaryLocation W20008186101 @default.
• W2000818610 hasRelatedWork W1223080974 @default.
• W2000818610 hasRelatedWork W2015248033 @default.
• W2000818610 hasRelatedWork W2123005889 @default.
• W2000818610 hasRelatedWork W2241382955 @default.
• W2000818610 hasRelatedWork W2344813946 @default.
• W2000818610 hasRelatedWork W2510735769 @default.
• W2000818610 hasRelatedWork W2536979495 @default.
• W2000818610 hasRelatedWork W2552976039 @default.
• W2000818610 hasRelatedWork W2566193491 @default.
• W2000818610 hasRelatedWork W2567364815 @default.
• W2000818610 hasRelatedWork W2571297828 @default.
• W2000818610 hasRelatedWork W2576728170 @default.
• W2000818610 hasRelatedWork W2588142421 @default.
• W2000818610 hasRelatedWork W2588545497 @default.
• W2000818610 hasRelatedWork W2591384843 @default.
• W2000818610 hasRelatedWork W2979796411 @default.
• W2000818610 hasRelatedWork W2981635608 @default.
• W2000818610 hasRelatedWork W3048700896 @default.
• W2000818610 hasRelatedWork W3197154165 @default.
• W2000818610 hasRelatedWork W602865235 @default.
• W2000818610 isParatext "false" @default.
• W2000818610 isRetracted "false" @default.
• W2000818610 magId "2000818610" @default.
• W2000818610 workType "article" @default.